Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

This is an announcement for a grant opportunity aimed at funding innovative research projects that focus on the development of advanced technologies for basic and clinical cancer research. The grant, known as the Innovative Molecular and Cellular Analysis Technologies (R61), rules out clinical trials.

The projects deemed appropriate for this grant should be exploratory in nature, primarily focused on the early-stage creation of cutting-edge technologies. These innovations should offer new ways of analyzing molecular or cellular elements. The grant particularly emphasizes the importance of technical innovation in enhancing our understanding of cancer biology through better targeting, probing, or assessing of molecular and cellular features.

The technologies proposed may have potential for wide-ranging applications, but should be specifically designed to improve the molecular and cellular characterization of cancer biology.

Applications are especially sought from projects that have the potential to speed up or improve research in varied areas of cancer biology, such as early detection and screening, clinical diagnosis, treatment, control, epidemiology. The grant also encourages projects that address issues related to cancer health disparities.

This funding opportunity is part of the larger Innovative Molecular Analysis Technologies (IMAT) Program sponsored by the National Cancer Institute (NCI).